Evidence map›Paper›PMID 41198671›Full record

ArticleCell death & disease2025

HER3 promotes triple-negative breast cancer progression by upregulating PHF8 via miR-34b-5p-dependent mechanism.

Hui Lyu, CongCong Tan, Yakun Wu, Margaret E Larsen, Qingzhao Yu, Guobin Kang, Charles Wood, Shou-Ching Tang, Bolin Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hui LyuDepartment of Interdisciplinary Oncology, Stanley S. Scott Cancer Center, School of Medicine, LSU Health Sciences Center, New Orleans, LA, USA. hlyu@lsuhsc.edu.ORCID http://orcid.org/0000-0003-1851-2533
CongCong TanDepartment of Interdisciplinary Oncology, Stanley S. Scott Cancer Center, School of Medicine, LSU Health Sciences Center, New Orleans, LA, USA.
Yakun WuDepartment of Interdisciplinary Oncology, Stanley S. Scott Cancer Center, School of Medicine, LSU Health Sciences Center, New Orleans, LA, USA.
Margaret E LarsenDepartment of Interdisciplinary Oncology, Stanley S. Scott Cancer Center, School of Medicine, LSU Health Sciences Center, New Orleans, LA, USA.
Qingzhao YuBiostatistics and Data Science, School of Public Health, LSU Health Sciences Center, New Orleans, LA, USA.
Guobin KangDepartment of Interdisciplinary Oncology, Stanley S. Scott Cancer Center, School of Medicine, LSU Health Sciences Center, New Orleans, LA, USA.
Charles WoodDepartment of Interdisciplinary Oncology, Stanley S. Scott Cancer Center, School of Medicine, LSU Health Sciences Center, New Orleans, LA, USA.
Shou-Ching TangDepartment of Medicine, LSU LCMC Health Cancer Center, School of Medicine, LSU Health Sciences Center, New Orleans, LA, USA.
Bolin LiuDepartment of Interdisciplinary Oncology, Stanley S. Scott Cancer Center, School of Medicine, LSU Health Sciences Center, New Orleans, LA, USA. bliu2@lsuhsc.edu.ORCID http://orcid.org/0000-0003-0150-8650

Funding

Investigate interactive roles of environmental, behavioral and genetic factors on racial disparities in breast cancer outcomesR01CA260698 · NCI · UNIVERSITY OF GEORGIA · PI XI, YAGUANG · 2021 to 2025
$2.0M
HER3-PHF8 signaling axis in triple-negative breast cancer progressionR01CA266269 · NCI · LSU HEALTH SCIENCES CENTER · PI Bolin Liu · 2023 to 2026
$1.6M
Interactions between ES-miRNAs and environmental risk factors are responsible for TNBC progression and associated racial health disparities: a novel analysis with multilevel moderation inferencesR01CA275089 · NCI · LSU HEALTH SCIENCES CENTER · PI Yaguang Xi, Qingzhao Yu · 2023 to 2026
$1.3M
Trends of disparities in breast cancer progression and health care considering multilevel risk factorsR15MD012387 · NIMHD · LSU HEALTH SCIENCES CENTER · PI YU, QINGZHAO · 2017 to 2023
$1.1M
NCI NIH HHS R01 CA260698NCI NIH HHS R01 CA266269NCI NIH HHS R01 CA275089NIMHD NIH HHS R15 MD012387U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA260698U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA266269
6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is one of the most aggressive subtypes of breast cancer, with limited targeted treatment options and poor clinical outcomes. HER3 has recently emerged as a promising therapeutic target, with HER3-directed antibody-drug conjugates advancing to Phase III clinical trials for non-small cell lung cancer. However, the downstream molecular mechanisms by which HER3 promotes TNBC progression remain poorly defined. In this study, we uncovered a previously unrecognized HER3/miR-34b-5p/PHF8 signaling axis that drives TNBC cell proliferation and tumor growth. Mechanistically, HER3 activation suppresses the tumor-suppressive microRNA miR-34b-5p, resulting in the upregulation of the histone demethylase PHF8 (KDM7B), which in turn represses the expression of the CDK inhibitor p27

Indexed as

Histone DemethylasesMicroRNAsReceptor, ErbB-3Transcription FactorsTriple Negative Breast NeoplasmsAnimalsCell Line, TumorCell ProliferationDisease ProgressionFemaleGene Expression Regulation, NeoplasticHumansMiceMice, NudeSignal TransductionUp-RegulationERBB3 protein, humanHistone DemethylasesMicroRNAsMIRN34 microRNA, humanPHF8 protein, humanReceptor, ErbB-3Transcription Factors

Identifiers

PMID41198671
PMCPMC12592479

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.